Group 1 - GSK has entered the weight loss market by acquiring 35Pharma and introducing the HS235 drug for fat-selective weight loss and muscle mass preservation [1] - GSK's shares have increased by 38% over the past year, reflecting positive market sentiment since Jim Cramer recommended the stock in March 2025 [1] - The company reported fourth-quarter earnings of 8.6 billion pounds in revenue and 25.5 pence in earnings per share, surpassing analyst expectations [1] Group 2 - Following the third-quarter earnings report, GSK raised its 2025 revenue growth estimates from 3%-5% to 6%-7%, with reported revenue of 8.6 billion pounds and earnings per share of 55 pence [1] - Jim Cramer praised GSK, highlighting its low price-to-earnings ratio and 4% yield, indicating it as a strong investment opportunity [1]

Group 1 - The article recommends buying the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM), marking the first discussion of this thematic ETF type [1] - The author previously wrote an investment thesis on Eli Lilly, indicating a focus on companies involved in the GLP-1 and weight loss sector [1] Group 2 - The author has over 7 years of experience in equity analysis in Latin America, providing in-depth research and insights for informed investment decisions [1]